Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 7:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: L-tyrosine Clear all
Recruiting No phase listed Observational

Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia

NCT06229860
View directory record Official record
Conditions
Chronic Myeloid Leukemia, Chronic Phase Chronic Myelogenous Leukemia
Interventions
Interview
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 26, 2026, 7:15 AM EDT
Active, not recruiting Phase 1 Interventional

Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor

NCT02496663
View directory record Official record
Conditions
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Elastography, Multigated Acquisition Scan, Necitumumab, Osimertinib
Procedure · Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
15
States / cities
Duarte, California • Palo Alto, California • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 26, 2026, 7:15 AM EDT
Completed Phase 2 Interventional Results available

Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

NCT03836209
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Gilteritinib, Midostaurin, Daunorubicin, Cytarabine
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years to 70 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
44
States / cities
Scottsdale, Arizona • Clovis, California • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 26, 2026, 7:15 AM EDT
Completed Phase 1 Interventional

A Phase I Trial of Capecitabine in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer

NCT00480584
View directory record Official record
Conditions
Metastatic Pancreatic Carcinoma
Interventions
gemcitabine, capecitabine, erlotinib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 7, 2012 · Synced Sep 26, 2026, 7:15 AM EDT
Completed Phase 2 Interventional Results available

A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed

NCT03890731
View directory record Official record
Conditions
Solid Cancer
Interventions
BAY73-4506 (Regorafenib, Stivarga)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Sep 26, 2026, 7:15 AM EDT
Completed Phase 3 Interventional Results available

Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)

NCT03515837
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
pembrolizumab, pemetrexed, carboplatin, cisplatin, saline solution
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
492 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
19
States / cities
Los Angeles, California • Monterey, California • Orange, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Sep 26, 2026, 7:15 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

NCT04868877
View directory record Official record
Conditions
Non-Small Cell Lung Cancer Metastatic, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
Interventions
MCLA-129, Osimertinib, Chemotherapy
Drug
Lead sponsor
Merus B.V.
Industry
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
4
States / cities
Orange, California • Nashville, Tennessee • West Valley City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 26, 2026, 7:15 AM EDT
Completed Phase 3 Interventional Results available

A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)

NCT02997202
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
gilteritinib, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
46
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Sep 26, 2026, 7:15 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

NCT04240002
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)
Interventions
gilteritinib, fludarabine, cytarabine, granulocyte colony-stimulating factor (G-CSF)
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
6 Months to 21 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 4, 2026 · Synced Sep 26, 2026, 7:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Levodopa Response and Gut Microbiome in Patients With Parkinson's Disease

NCT04956939
View directory record Official record
Conditions
Parkinson Disease
Interventions
Low dose levodopa, High dose levodopa
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
40 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 6, 2022 · Synced Sep 26, 2026, 7:15 AM EDT
Completed Phase 1 Interventional

Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck

NCT00083057
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
gefitinib, paclitaxel, radiation therapy
Drug · Radiation
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Sep 26, 2026, 7:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression

NCT02891603
View directory record Official record
Conditions
Graft Vs Host Disease, GVHD
Interventions
Pacritinib, Sirolimus, Tacrolimus, Allogenic hematopoietic cell transplant (alloHCT)
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
Tampa, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 26, 2026, 7:15 AM EDT
Terminated Phase 2 Interventional Results available

Sunitinib in Certain Subtypes of Soft Tissue Sarcomas

NCT00859456
View directory record Official record
Conditions
Sarcoma, Soft Tissue
Interventions
Sunitinib
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2019 · Synced Sep 26, 2026, 7:15 AM EDT
Recruiting Phase 1Phase 2 Interventional

Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)

NCT07049926
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Belzutifan, Zanzalintinib
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 120 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
7
States / cities
San Francisco, California • Mineola, New York • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 26, 2026, 7:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate The Effect of Ketoconazole on the Pharmacokinetics of Tivozanib in Healthy Subjects

NCT01363778
View directory record Official record
Conditions
Healthy
Interventions
tivozanib
Drug
Lead sponsor
AVEO Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 4, 2012 · Synced Sep 26, 2026, 7:15 AM EDT
Completed No phase listed Observational

Treatment Patterns and Key Endpoints Among Patients With Chronic-Phase Chronic Myeloid Leukemia in a Community Oncology Setting

NCT07374120
View directory record Official record
Conditions
Leukemia, Myeloid, Chronic-Phase
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Sep 26, 2026, 7:15 AM EDT
Terminated Phase 2 Interventional Results available

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

NCT03737994
View directory record Official record
Conditions
Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Alectinib, Brigatinib, Carboplatin, Ceritinib, Cisplatin, Crizotinib, Ensartinib, Lorlatinib, Pemetrexed
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
491
States / cities
Goodyear, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 341 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 26, 2026, 7:15 AM EDT
Withdrawn Phase 2 Interventional

Iressa/Docetaxel in Non-Small-Cell Lung Cancer

NCT00048087
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
ZD1839, Docetaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Sep 26, 2026, 7:15 AM EDT
Completed Phase 1 Interventional

Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors

NCT00483366
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
capecitabine, gemcitabine hydrochloride, imatinib mesylate, mutation analysis, nucleic acid sequencing, polymerase chain reaction
Drug · Genetic
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 120 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 22, 2024 · Synced Sep 26, 2026, 7:15 AM EDT
Completed Phase 2 Interventional Results available

Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19

NCT04440007
View directory record Official record
Conditions
Covid-19
Interventions
Abivertinib, Standard of Care
Drug · Other
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Brandon, Florida • Alexandria, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Sep 26, 2026, 7:15 AM EDT
Completed Phase 3 Interventional Results available

Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)

NCT02668653
View directory record Official record
Conditions
Acute Myeloid Leukemia, Leukemia
Interventions
Chemotherapy, Quizartinib, Placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
11
States / cities
Gainesville, Florida • Chicago, Illinois • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Sep 26, 2026, 7:15 AM EDT
Completed Phase 2 Interventional

Behavioral Therapy Combined With Carbidopa/Levodopa for the Treatment of Cocaine Dependence

NCT00218075
View directory record Official record
Conditions
Cocaine Abuse, Cocaine-Related Disorders
Interventions
Levodopa, Carbidopa, Clinical Management, Relapse Prevention Therapy, Contingency Management
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 55 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2016 · Synced Sep 26, 2026, 7:15 AM EDT
Active, not recruiting Phase 3 Interventional

COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME

NCT07449936
View directory record Official record
Conditions
Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)
Interventions
EYP-1901, Aflibercept (2.0 mg)
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
53
States / cities
Bakersfield, California • Encino, California • Glendale, California + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 26, 2026, 7:15 AM EDT
Completed Phase 1 Interventional

A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

NCT03236857
View directory record Official record
Conditions
Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Non-Hodgkin's Lymphoma, Neuroblastoma
Interventions
chemotherapy, venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
0 Years to 25 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
11
States / cities
San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated May 21, 2023 · Synced Sep 26, 2026, 7:15 AM EDT